An announcement, made on February 2, 2022, heralded the return of an initiative begun under President Barack Obama in 2016, when President Biden was vice president.
President Jospeh R. Biden relaunched the Cancer Moonshot program with the goals of reducing the cancer death rate by at least 50% over the next 25 years, improving the experience of patients, and ultimately eradicating the disease.1
The announcement, made on February 2, 2022, heralded the return of an initiative begun under President Barack Obama in 2016, when Biden was vice president.1
The Biden administration has made the Cancer Moonshot part of its health care agenda, which also prioritizes lowering health care costs and expanding patient coverage. Specific Cancer Moonshot goals include diagnosing cases earlier, addressing environmental exposures, dealing with inequities in access to treatment, accelerating the fight against pediatric cancers, and learning from the experiences of all patients.1
Biden said the initiative has bipartisan support and may garner attention from other nations but added that it will be expensive.2 “I’m also calling on the scientifi c and medical communities to bring the boldest thinking to this fi ght,” he said during remarks made in the East Room of the White House. “I’m calling on the private sector to develop and test new treatments, make drugs more affordable, and share more data and knowledge that can inform the public and benefi t every company’s research.”2
The nation’s response to the COVID-19 pandemic and the development of vaccines spurred the White House and investigators to explore the use of messenger RNA (mRNA) technology in the fi ght against cancer. The mRNA vaccines, designed to create an immune response to existing cancer, could also target some proteins made by tumors.3
Biden also discussed plans for the Advanced Research Projects Agency for Health (ARPA-H), intended to strengthen the government’s ability to prevent, detect, and treat a variety of diseases including cancer.1 “The White House Offi ce of Science and Technology Policy, led by senior scientist and adviser [Eric Lander, PhD]…will chart the path for the Cancer Moonshot for 2022 and beyond,” the President said. “And I’m calling on Congress to fund my proposed ARPA-H.... This will be a new kind of entity within the National Institutes of Health…with autonomy and authorities to drive unprecedented progress in biomedicine.”2
REFERENCES:
1. Fact sheet: President Biden reignites Cancer Moonshot to end cancer as we know it. The White House. February 2, 2022. Accessed February 24, 2022. https://www.whitehouse.gov/briefi ng-room/ statements-releases/2022/02/02/fact-sheet-president-biden-reignites-cancer-moonshot-to-end-cancer-as-we-know-it/
2. Remarks by President Biden at an event to reignite the Cancer Moonshot. The White House. February 2, 2022. Accessed February 24, 2022. https://www.whitehouse.gov/briefi ng-room/speeches-remarks/2022/02/02/remarks-by-president-biden-at-an-event-to-reignite-the-cancer-moonshot/
3. Kaiser J. Biden’s ‘reignited’ Cancer Moonshot would develop blood tests to detect cancer and vaccines to prevent it. Science. February 2, 2022. Accessed February 24, 2022. https://www.science.org/ content/article/biden-s-reignited-cancer-moonshot-would-developblood-tests-detect-cancer-and-vaccines
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More